ATE447613T1 - Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten - Google Patents

Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten

Info

Publication number
ATE447613T1
ATE447613T1 AT98963460T AT98963460T ATE447613T1 AT E447613 T1 ATE447613 T1 AT E447613T1 AT 98963460 T AT98963460 T AT 98963460T AT 98963460 T AT98963460 T AT 98963460T AT E447613 T1 ATE447613 T1 AT E447613T1
Authority
AT
Austria
Prior art keywords
retain
binding site
site domains
domains
identifying
Prior art date
Application number
AT98963460T
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Katrin Borschert
Florian Zettl
Ralf Lutterbuese
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Application granted granted Critical
Publication of ATE447613T1 publication Critical patent/ATE447613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT98963460T 1997-11-17 1998-11-16 Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten ATE447613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120096 1997-11-17
PCT/EP1998/007313 WO1999025818A1 (en) 1997-11-17 1998-11-16 Method of identifying binding site domains that retain the capacity of binding to an epitope

Publications (1)

Publication Number Publication Date
ATE447613T1 true ATE447613T1 (de) 2009-11-15

Family

ID=8227629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963460T ATE447613T1 (de) 1997-11-17 1998-11-16 Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten

Country Status (13)

Country Link
US (1) US7435549B1 (de)
EP (1) EP1032660B1 (de)
JP (2) JP4327350B2 (de)
AT (1) ATE447613T1 (de)
AU (1) AU1873199A (de)
CA (1) CA2309679C (de)
CY (1) CY1110699T1 (de)
DE (1) DE69841273D1 (de)
DK (1) DK1032660T3 (de)
ES (1) ES2334184T3 (de)
HK (1) HK1031740A1 (de)
PT (1) PT1032660E (de)
WO (1) WO1999025818A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
GB9917027D0 (en) * 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
JP2004500108A (ja) * 2000-03-24 2004-01-08 マイクロメット　アーゲー Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
AU2001279193A1 (en) * 2000-08-02 2002-02-13 Xencor Methods and compositions for the construction and use of viral envelops as display particles
NZ543202A (en) * 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
MX2016003744A (es) 2013-10-11 2016-08-11 Us Health Anticuerpos tem8 y su uso.
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3218397B8 (de) 2014-11-14 2021-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
HUE049081T2 (hu) 2015-03-20 2020-09-28 The United States Of America As GP120 elleni neutralizáló antitestek és alkalmazásuk
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
AU2017289270B2 (en) 2016-06-27 2023-05-04 The Regents Of The University Of California Cancer treatment combinations
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP3724223A1 (de) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralisierender antikörper gegen ebola-virus-glycoprotein und deren verwendung
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
JP2023547662A (ja) 2020-11-06 2023-11-13 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
US20240117011A1 (en) 2021-02-09 2024-04-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
EP4291306A1 (de) 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Menschliche monoklonale antikörper gegen pneumokokken-antigene
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE69233750D1 (de) * 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69331278T2 (de) * 1992-09-04 2002-07-18 Scripps Research Inst Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
PT699237E (pt) 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
CA2297070A1 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex

Also Published As

Publication number Publication date
AU1873199A (en) 1999-06-07
JP4977156B2 (ja) 2012-07-18
CA2309679A1 (en) 1999-05-27
CA2309679C (en) 2010-07-20
US7435549B1 (en) 2008-10-14
DE69841273D1 (de) 2009-12-17
EP1032660B1 (de) 2009-11-04
ES2334184T3 (es) 2010-03-05
DK1032660T3 (da) 2010-01-18
EP1032660A1 (de) 2000-09-06
JP2002508924A (ja) 2002-03-26
WO1999025818A1 (en) 1999-05-27
CY1110699T1 (el) 2015-06-10
HK1031740A1 (en) 2001-06-22
JP4327350B2 (ja) 2009-09-09
PT1032660E (pt) 2009-12-28
JP2009148280A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
ATE447613T1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
ATE230850T1 (de) Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
WO2004065416A3 (en) Synthetic antibody phage libraries
EP2141243A3 (de) Proteingerüste für Antikörpermimetika und andere Bindungsproteine
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
PT98113A (pt) Processo para a preparacao de proteinas de fusao com uma fraccao de imunoglobulina
DK1140175T3 (da) Antistoffer mod trunkeret VEGF-D og anvendelser deraf
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
WO1995023859A3 (en) Novel forms of t cells costimulatory molecules and uses therefor
ATE372382T1 (de) Ein faktor viii-polypeptid mit faktor viii:c- aktivität
ATE172247T1 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
DE69842225D1 (de) Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP2305710A3 (de) Synthetische Antikörperphagenbibliotheken
WO2004094615A3 (en) Prokaryotic collagen-like proteins and uses thereof
DE69513025D1 (de) Test für inhibitoren von dp-1 und anderen dp-proteinen
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
WO1998002557A3 (en) MAMMALIAN TNF-α CONVERTASES
ATE379967T1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032660

Country of ref document: EP